reference/8231541

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/8231541

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Comparative Study\|Journal Article\|Multicenter Study\|Randomized Controlled Trial
endingPage	3935
issn	1557-3265 1078-0432
issueIdentifier	15
pageRange	3928-3935
publicationName	Clinical cancer research : an official journal of the American Association for Cancer Research
startingPage	3928
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_315dd4e684f77e810ba825b650dd4b5a
bibliographicCitation	Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers S, Secord AA, Havrilesky L, O'Malley DM, Backes FJ, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi K, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD. Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis. Clin Cancer Res. 2020 Aug 01;26(15):3928–35. PMID: 32601075; PMCID: PMC8792803.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8e0bef20c7147934bda372d139473b67 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_68cd2809b20f9191eb968e7b9930ce9d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e9bb9808590c91a1a97338f466854242 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e36e73c0689b1a681d2a990f17bf57b4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2bd159bf469d7591fb071ee8dce8ce56 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_826f27954b28bea1228fe50262b121e7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-9824-6612 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-7098-6376 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6c9ec455faf7aba6dec4da1c751836d1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d1d43493eed6da610c0a69fda83917f4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-5680-0670 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1c16f3c69ea9df586d11ff9f98e2d222 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-9225-6913 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f998cd5f2a9ec882832bf3519a14482d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_74e93df46df81beb3d42d79c0464cb29 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b5b851d699c401163c7993ab759d32d8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c2fc13868fdca64ff6bbe58f3a68134e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8bb103d28814f94ed227b3c74fc33e57 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bbc205face0a2668271548b92d326143 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-1365-0411 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_178c740f4255e0f6ecab41d40984bde3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e627f04366d088b50b0d84709b831ebd http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_274d385ae536ee1ae9b37f85a69926e1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bdd31b31355c657c67cff2a844c31f74
date	2020-08-01^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/PMC8792803 https://pubmed.ncbi.nlm.nih.gov/32601075 https://doi.org/10.1158/1078-0432.ccr-20-0953
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/8794 https://portal.issn.org/resource/ISSN/1557-3265 https://portal.issn.org/resource/ISSN/1078-0432
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis
discusses	http://id.nlm.nih.gov/mesh/M0026156 http://id.nlm.nih.gov/mesh/M0028048 http://id.nlm.nih.gov/mesh/M0291428 http://id.nlm.nih.gov/mesh/M0024707 http://id.nlm.nih.gov/mesh/M0495206
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D016889Q000628 http://id.nlm.nih.gov/mesh/D000971Q000008 http://id.nlm.nih.gov/mesh/D009364Q000628 http://id.nlm.nih.gov/mesh/D018284Q000628
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D004717Q000473 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D000068878Q000008 http://id.nlm.nih.gov/mesh/D000077982 http://id.nlm.nih.gov/mesh/D065426 http://id.nlm.nih.gov/mesh/D017239Q000009 http://id.nlm.nih.gov/mesh/D017239Q000008 http://id.nlm.nih.gov/mesh/D016889Q000401 http://id.nlm.nih.gov/mesh/D016019 http://id.nlm.nih.gov/mesh/D005500 http://id.nlm.nih.gov/mesh/D018284Q000401 http://id.nlm.nih.gov/mesh/D016190Q000009 http://id.nlm.nih.gov/mesh/D016889Q000235 http://id.nlm.nih.gov/mesh/D016190Q000008 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D017024Q000379 http://id.nlm.nih.gov/mesh/D000971Q000009 http://id.nlm.nih.gov/mesh/D016889Q000175 http://id.nlm.nih.gov/mesh/D017024Q000009 http://id.nlm.nih.gov/mesh/D009367 http://id.nlm.nih.gov/mesh/D009364Q000175 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D000068878Q000009 http://id.nlm.nih.gov/mesh/D009364Q000401 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D009364Q000235 http://id.nlm.nih.gov/mesh/D018284Q000235 http://id.nlm.nih.gov/mesh/D018284Q000175 http://id.nlm.nih.gov/mesh/D018719Q000032 http://id.nlm.nih.gov/mesh/D018719Q000378 http://id.nlm.nih.gov/mesh/D004334 http://id.nlm.nih.gov/mesh/D004717Q000601
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID36314 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9567 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID426756 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_e8ad08f759b2798c1b5dca78861cc6ce http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10195 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9950 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_43830973f74de180729ad1e755d592ad http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID441037

Showing number of triples: 1 to 96 of 96.